The platform
An oncology-grade discovery engine.
We treat skin-aging proteins like drug targets and design the molecules that hit them. The output isn't a single molecule — it's a platform that produces pipelines.
Our approach
Drug the targets that age skin.
01 · Pick the driver
Select the proteins that drive each aging pathway — KEAP1, stratifin, MMP-12, GATA4 — and design binders or modulators against them.
02 · Design novel matter
Each design is novel chemical matter → patentable → a defensible asset the incumbents don't own.
03 · In silico first
Hundreds of candidates designed and filtered before any lab spend; only the best are nominated for validation.
The engine
From target to patentable molecule — by design.
The engine invents every candidate, then forces it to survive seven independent computational gates — and a final adversarial review — before it earns a place in our IP portfolio.
Tenth-Man adversarial review. Once a candidate clears all seven gates, the completed run is attacked with decoys, positive controls and attractor detection. Only a result it cannot refute proceeds to filing.
One automated pipeline — an orchestrated stack of 40+ computational tools, calibrated against experimental ground truth.
Calibration
We know exactly where it works.
On molecules with known answers, the engine's rankings track reality — and we mapped the boundary where they don't. That discipline is why the leads are trustworthy.
Affinity-ranking correlation
Predicted vs. measured binding, on known-answer sets.
Binder-vs-decoy separation
True binders cleanly separated from decoys (0.92–0.996).
Target-class × modality competency map
A calibrated generator that is honest about its limits beats one that flatters every molecule.
Where it was proven
Validated where it's hardest: cancer therapeutics.
The engine was built and calibrated on intractable oncology targets — including RAS isoforms (KRAS / HRAS / NRAS) and other "undruggable" proteins. The methodology is proven on the hardest problems in drug discovery; skin is a more tractable application of the same engine.
Calibrated against ground truth
Known-binder affinity ladders, co-crystal structures, decoy-enrichment tests, and positive controls.
We caught our own failure modes — sequence-integrity checks, consensus requirements, and honest "missing-data" flags.
Why the platform is valuable
Defensible value, created before the lab bill.
Speed & cost
Design and triage hundreds of candidates computationally before committing wet-lab dollars.
Novelty by construction
De novo design yields new, patentable chemical matter — not tweaks of generic actives.
De-risked selection
Consensus scoring and honest gates filter weak designs early — built to reject, not flatter.
Capital-efficient
IP is locked before the lab bill — the cheapest possible way to create defensible value.
Reusable
The same engine attacks any new target — each program extends the asset.
A platform that produces pipelines — not a single product.